Renal denervation and hypertension

American Journal of Hypertension

Volumn 24, Issue 6, 2011, Pages 635-642

  Schlaich, Markus P ^a   Krum, Henry ^b   Sobotka, Paul A ^c,d   Esler, Murray D ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d ARDIAN Inc   (United States)

Author keywords

blood pressure; hypertension; renal denervation; sympathetic

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERANCE; EFFERENT NERVE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY NERVE; LIFESTYLE MODIFICATION; MINIMALLY INVASIVE PROCEDURE; NERVE SURGERY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NERVE; SPLANCHNICECTOMY; SURGICAL TECHNIQUE; SYMPATHECTOMY; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE;

AGED; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CATHETER ABLATION; DENERVATION; HUMANS; HYPERTENSION; KIDNEY; MIDDLE AGED; RISK; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 79956114384     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.35     Document Type: Article

References (62)

1. Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007; 50:991-997. (Pubitemid 350172916)
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223. (Pubitemid 40138015)
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206. (Pubitemid 37430058)
4. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52:1749-1757.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
6. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-2082. (Pubitemid 37430209)
7. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton B P, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393-404. (Pubitemid 35469393)
8. Calhoun DA, Jones D, Textor S, Goff DC, Murphy T P, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
9. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953; 152:1501-1504.
10. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953; 1:403-408.
11. Barajas L. Innervation of the renal cortex. Fed Proc 1978; 37:1192-1201. (Pubitemid 8314398)
12. Bell-Reuss E, Trevino DL, Gottschalk CW. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976; 57:1104-1107.
13. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989; 67:858-864. (Pubitemid 19208123)
14. Kon V. Neural control of renal circulation. Miner Electrolyte Metab 1989; 15:33-43. (Pubitemid 19013523)
15. Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 1977; 56:691-698. (Pubitemid 8235170)
16. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986; 8 Suppl 5:S39-S43. (Pubitemid 16039090)
17. Schlaich M P, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43:169-175. (Pubitemid 38174169)
18. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989; 2:140S-146S. (Pubitemid 19082354)
19. Schlaich M P, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565. (Pubitemid 36961170)
20. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11:723-728. (Pubitemid 28313692)
21. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15:717-724. (Pubitemid 34804278)
22. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 2000; 75:S2-S6. (Pubitemid 30205432)
23. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25:878-882.
24. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26:861-865.
25. Katholi RE. Renal nerves and hypertension: an update. Fed Proc 1985; 44:2846-2850. (Pubitemid 16229758)
26. Katholi RE, Winternitz SR, Oparil S. Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 1982; 69:55-62. (Pubitemid 12212245)
27. O'Hagan K P, Thomas GD, Zambraski EJ. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens 1990; 3:62-64. (Pubitemid 20077356)
28. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger J P. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25:893-897.
29. Whitworth JA, Denton DA, Graham W F, Humphery TJ, Scoggins BA, Coghlan J P. The effect of renal denervation on ACTH-induced hypertension in sheep. Clin Exp Pharmacol Physiol 1981; 8:203-207. (Pubitemid 11065922)
30. DiBona GF. Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 2005; 289:R633-R641.
31. DiBona GF, Sawin LL. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol 1991; 260:R298-R305.
32. Villarreal D, Freeman RH, Johnson RA, Simmons JC. Effects of renal denervation on postprandial sodium excretion in experimental heart failure. Am J Physiol 1994; 266:R1599-R1604.
33. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197. (Pubitemid 27069290)
34. Norman RA Jr, Murphy WR, Dzielak DJ, Khraibi AA, Carroll RG. Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 1984; 6:622-626. (Pubitemid 15210501)
35. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11:197-200.
36. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997; 10:184-187. (Pubitemid 27333193)
37. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706. (Pubitemid 38405571)
38. Peet MM, Isberg EM. The surgical treatment of essential hypertension. J Am Med Assoc 1946; 130:467-473.
39. Smithwick RH. Surgical treatment of hypertension. Am J Med 1948; 4:744-759.
40. Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg 1941; 114:753-775.
41. Maitland AI. The effect of splanchnicectomy on renal function. Lancet 1950; 2: 7-10.
42. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham W T, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
43. Esler MD, Krum H, Sobotka PA, Schlaich M P, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
44. Schlaich M, Krum H, Walton T, Whitbourn R, Sobotka P, Esler, M. Two-year durability of blood pressure reduction with catheter-based renal sympathetic denervation. J Hypertens 2010; 28: E446.
45. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641-1650. (Pubitemid 26364270)
46. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
47. Schlaich M P, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932-934.
48. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci 1994; 87:13-20. (Pubitemid 24220266)
49. Petersson MJ, Rundqvist B, Johansson M, Eisenhofer G, Lambert G, Herlitz H, Jensen G, Friberg P. Increased cardiac sympathetic drive in renovascular hypertension. J Hypertens 2002; 20:1181-1187. (Pubitemid 34913638)
50. Pettersson A, Hedner J, Hedner T. Renal interaction between sympathetic activity and ANP in rats with chronic ischaemic heart failure. Acta Physiol Scand 1989; 135:487-492. (Pubitemid 19115197)
51. Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, Inoue H. Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 2002; 16:51-56. (Pubitemid 34110714)
52. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. A m J Physiol Renal Physiol 2011; 300:F31-F39.
53. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918. (Pubitemid 23006966)
54. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328. (Pubitemid 29196594)
55. Schlaich M P, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20:933-939.
56. Grassi G, Seravalle G, Arenare F, Buccianti G, Furiani S, Ilardo V, Bolla G, Mancia G. Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. J Hypertens 2009; 27:562-566.
57. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 2008; 105:1873-1876.
58. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21:1709-1717. (Pubitemid 37076355)
59. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359. (Pubitemid 34260428)
60. Burns J, Sivananthan MU, Ball SG, Mackintosh A F, Mary DA, Greenwood J P. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 2007; 115:1999-2005. (Pubitemid 46625950)
61. Luippold G, Beilharz M, Mühlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19: 342-347. (Pubitemid 38195982)
62. Strojek K, Grzeszczak W, Górska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12:602-605. (Pubitemid 32180031)